Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Synlogic, Inc. SYBX

Healthcare — Biotechnology
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

Synlogic, Inc. (SYBX) Business Profile

Company Overview

Synlogic, Inc. (SYBX) is a pioneering biotechnology company that specializes in the development of synthetic biotics, a novel class of living medicines. Founded in 2013, Synlogic is headquartered in Cambridge, Massachusetts, and was co-founded by Dr. Jim Collins and Dr. Tim Lu, both of whom are renowned experts in synthetic biology. The company went public in 2017 and is listed on the NASDAQ under the ticker symbol SYBX. Synlogic’s leadership team includes Dr. Aoife Brennan, who serves as the President and Chief Executive Officer, and brings extensive experience in drug development and commercialization. The company’s mission is to harness the power of synthetic biology to develop innovative therapies for patients with unmet medical needs.

Core Business Segments

Synlogic focuses on the development of synthetic biotics, which are engineered probiotics designed to treat a variety of diseases. The company’s core business segments include:

1. Metabolic Disorders

Synlogic is developing synthetic biotics to address metabolic disorders, such as phenylketonuria (PKU). Its lead product candidate, SYNB1934, is designed to lower blood phenylalanine levels in patients with PKU, a rare genetic disorder that affects the body’s ability to break down phenylalanine, an amino acid found in protein-rich foods.

2. Immuno-Oncology

The company is also exploring the use of synthetic biotics in immuno-oncology. By engineering probiotics to modulate the immune system, Synlogic aims to develop therapies that can enhance the body’s ability to fight cancer.

3. Gastrointestinal and Inflammatory Diseases

Synlogic is investigating synthetic biotics for the treatment of gastrointestinal and inflammatory diseases. These therapies are designed to restore balance to the gut microbiome and reduce inflammation, offering potential solutions for conditions such as inflammatory bowel disease (IBD).

4. Rare Diseases

In addition to PKU, Synlogic is exploring synthetic biotics for other rare diseases, leveraging its platform to address conditions with limited treatment options.

Business Model

Synlogic’s business model is centered around the development and commercialization of synthetic biotics. The company integrates cutting-edge synthetic biology techniques with rigorous clinical development to create living medicines that address unmet medical needs. Revenue generation is primarily focused on:

  • Collaborations and Partnerships: Synlogic collaborates with pharmaceutical companies and research institutions to advance its pipeline and expand the applications of its synthetic biotics platform.
  • Licensing Agreements: The company licenses its technology to partners, generating revenue through upfront payments, milestone payments, and royalties.
  • Product Sales: Once its therapies receive regulatory approval, Synlogic plans to generate revenue through the commercialization of its synthetic biotics.

Strategic Direction

Synlogic is committed to advancing its pipeline of synthetic biotics and expanding its platform’s capabilities. Key strategic priorities include:

  • Pipeline Expansion: The company aims to broaden its portfolio by developing synthetic biotics for additional indications, including rare diseases and chronic conditions.
  • Regulatory Approvals: Synlogic is focused on advancing its lead candidates through clinical trials and securing regulatory approvals to bring its therapies to market.
  • Sustainability Goals: Synlogic is dedicated to sustainable practices in its research and development processes, minimizing environmental impact while maximizing therapeutic potential.
  • Global Reach: The company plans to expand its presence in international markets, leveraging partnerships to bring its therapies to patients worldwide.

Competitive Landscape

Synlogic operates in a competitive biotechnology landscape, with key competitors including:

  • Seres Therapeutics: Focused on microbiome-based therapeutics.
  • Bluebird Bio: Specializes in gene and cell therapies for rare diseases.
  • Intrexon Corporation: Develops synthetic biology solutions across various industries, including healthcare.
  • Ginkgo Bioworks: Provides synthetic biology services and solutions.

Despite the competition, Synlogic differentiates itself through its proprietary synthetic biotics platform and focus on living medicines.

Risk Factors

Synlogic faces several risks that could impact its business, including:

  • Regulatory Challenges: The development and approval of synthetic biotics involve complex regulatory processes, which could delay or hinder commercialization.
  • Market Dependence: The company’s success is heavily reliant on the approval and adoption of its lead product candidates.
  • Supply Chain Disruptions: Manufacturing and supply chain issues could affect the production and distribution of synthetic biotics.
  • Financial Risks: As a clinical-stage company, Synlogic depends on external funding to support its operations and may face financial constraints.

Recent Developments

Synlogic has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trials: The company has reported positive data from clinical trials of SYNB1934 for PKU, demonstrating its potential to lower blood phenylalanine levels.
  • Partnerships: Synlogic has entered into collaborations with leading pharmaceutical companies to explore new applications for its synthetic biotics platform.
  • Innovation: The company continues to enhance its synthetic biology capabilities, incorporating advanced technologies to improve the efficacy and safety of its therapies.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of innovative healthcare solutions, driving interest in Synlogic’s synthetic biotics.

Investment Considerations

Investors considering Synlogic should weigh the following strengths and risks:

Strengths

  • Innovative Platform: Synlogic’s proprietary synthetic biotics platform positions it as a leader in the emerging field of living medicines.
  • Strong Pipeline: The company has a robust pipeline of product candidates targeting high-value indications.
  • Experienced Leadership: Synlogic’s management team brings extensive expertise in biotechnology and drug development.

Risks

  • Clinical and Regulatory Uncertainty: The success of Synlogic’s therapies depends on positive clinical trial outcomes and regulatory approvals.
  • Financial Dependence: As a pre-commercial company, Synlogic relies on external funding and may face financial challenges.
  • Competitive Pressure: The biotechnology sector is highly competitive, with numerous companies pursuing similar therapeutic approaches.

Conclusion

Synlogic, Inc. is at the forefront of synthetic biology, leveraging its innovative platform to develop synthetic biotics for a range of diseases. With a strong pipeline, strategic partnerships, and a commitment to addressing unmet medical needs, the company is well-positioned for growth. However, investors should carefully consider the risks associated with clinical-stage biotechnology companies. As Synlogic advances its therapies and expands its platform, it has the potential to make a significant impact on the healthcare landscape.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us